43
Participants
Start Date
July 30, 2022
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2028
Sintilimab (PD-1 Antibody)
Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
Cancer Hospital of Guangxi Medical University
OTHER